Search Clinical Trials
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Select a Condition or Specialty
- Allergy
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Cardiology
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19 (Coronavirus)
- Cystic Fibrosis
- Eczema (Atopic Dermatitis)
- Environmental & Occupational Health
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Food Allergy
- Gastroenterology
- Idiopathic Pulmonary Fibrosis (IPF)
- Interstitial Lung Disease (Pulmonary Fibrosis)
- Lung Cancer
- Nontuberculous Mycobacteria (NTM)
- Oncology
- Pulmonary Hypertension (PH)
- Respiratory (Pulmonary)
- Rheumatology
- Sarcoidosis
All Clinical Trials
BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six clinic visits over up to 34 weeks
.jpg?lang=en-US&ext=.jpg)
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- Monthly visits over 50-week timeframe
Biomarkers & Hypersensitivity Pneumonitis Progression
Are biomarkers in the blood of patients with hypersensitivity pneumonitis (HP) predictive? Researchers understand if biomarkers can help doctors understand how quickly the disease will progress
- Gender
- Any
- Ages
- 18-80
- Compensation
- Not Provided
- Time Required
- Not Specified
Predicting ILD from Hypersensitivity Pneumonitis
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- Clinic visits every 6 months over approximately 2 years (4 visits total)
Link Between Rheumatoid Arthritis & Lung Disease
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 6 in-person visits, performed every year over 4 years
ILD & Early Rheumatoid Arthritis
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- 5 in-person visits over 18 months
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
- Gender
- Any
- Ages
- 40-95
- Compensation
- Provided
- Time Required
- 5 visits over a 6-month period, visits are every 3 months
Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified
Adult Trials
BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six clinic visits over up to 34 weeks
Biomarkers & Hypersensitivity Pneumonitis Progression
Are biomarkers in the blood of patients with hypersensitivity pneumonitis (HP) predictive? Researchers understand if biomarkers can help doctors understand how quickly the disease will progress
- Gender
- Any
- Ages
- 18-80
- Compensation
- Not Provided
- Time Required
- Not Specified
Predicting ILD from Hypersensitivity Pneumonitis
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- Clinic visits every 6 months over approximately 2 years (4 visits total)
Link Between Rheumatoid Arthritis & Lung Disease
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- 6 in-person visits, performed every year over 4 years
ILD & Early Rheumatoid Arthritis
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
- Gender
- Any
- Ages
- 18-90
- Compensation
- Not Provided
- Time Required
- 5 in-person visits over 18 months
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
- Gender
- Any
- Ages
- 40-95
- Compensation
- Provided
- Time Required
- 5 visits over a 6-month period, visits are every 3 months
Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified
Pediatric Trials
Healthy Participant Trials
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- Monthly visits over 50-week timeframe